Ovarian aging
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 55 years; 2. The diagnosis of women is one of DOR, POI, early menopause or menopausal syndrome and wish to improve ovarian function or menopausal syndrome; 3. Sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. The patient is known to be allergic to or unsuitable to the Chinese herbal compound; 2. Women who are pregnant and lactating; 3. Patients with POI or DOR had been in menopause for more than 1 year; 4. Abnormal uterine bleeding, except for ovulation disorders; 5. Women who are taking hormone drugs and have stopped taking them within 3 months; 6. The diagnosis of women is endometriosis, myadenosis, submucosal fibroids or the size of non-submucosal fibroids is greater than 4 cm; 7. The nature of pelvic mass is unknown; 8. The diagnosis of women is polycystic ovary syndrome, hyperprolactinemia, hyperandrogenemia, diabetes, thyroid, and adrenal dysfunction, and other endocrine diseases affecting ovulation; 9. Complicated with serious primary diseases such as cardiovascular, liver, kidney, lung, biliary, hematopoietic system (Hb<90g/L) and malignant tumor, and psychiatric patients; 10. Patients who are participating in other clinical trials or have participated in other clinical trials within the last month; 11. Patients who are unsuitable for the study evaluated by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sex hormone;AMH, Anti-millerian hormone;Menstruation recovery rate;AFC, Number of antral follicles;Patient’s life quality; | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety assessment; | — |
Countries
China
Contacts
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology